Diversified Trust Co. cut its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 28.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,455 shares of the healthcare product maker's stock after selling 26,204 shares during the quarter. Diversified Trust Co.'s holdings in Abbott Laboratories were worth $5,939,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of the stock. 4WEALTH Advisors Inc. lifted its holdings in shares of Abbott Laboratories by 25.3% during the second quarter. 4WEALTH Advisors Inc. now owns 9,520 shares of the healthcare product maker's stock valued at $883,000 after purchasing an additional 1,923 shares during the last quarter. Liberty Capital Management Inc. purchased a new position in Abbott Laboratories in the 2nd quarter worth about $3,140,000. Merit Financial Group LLC raised its holdings in Abbott Laboratories by 22.0% during the 2nd quarter. Merit Financial Group LLC now owns 77,835 shares of the healthcare product maker's stock worth $7,063,000 after buying an additional 14,030 shares during the period. Vaquero Private Wealth Ltd. purchased a new stake in Abbott Laboratories during the second quarter valued at about $180,000. Finally, Farther Finance Advisors LLC boosted its holdings in shares of Abbott Laboratories by 1.5% in the second quarter. Farther Finance Advisors LLC now owns 73,946 shares of the healthcare product maker's stock worth $6,714,000 after buying an additional 1,128 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.
Abbott Laboratories Trading Down 0.5%
Abbott Laboratories stock opened at $110.68 on Tuesday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company's fifty day moving average price is $98.08 and its two-hundred day moving average price is $99.79. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market capitalization of $191.52 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 2.15 and a beta of 0.59.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio is currently 81.55%.
Analysts Set New Price Targets
Several equities analysts have weighed in on ABT shares. Piper Sandler reiterated an "overweight" rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Argus reduced their target price on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, April 21st. UBS Group decreased their target price on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th. Daiwa Securities Group lowered Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price target on the stock. in a research report on Wednesday, April 22nd. Finally, Leerink Partners reduced their price objective on Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $118.67.
Check Out Our Latest Stock Analysis on Abbott Laboratories
Abbott Laboratories Company Profile
(
Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
